Structure-Based Drug Design and Characterization of Sulfonyl-Piperazine Benzothiazinone Inhibitors of DprE1 from Mycobacterium tuberculosis.

Piton, Jérémie; Vocat, Anthony; Lupien, Andréanne; Foo, Caroline S; Riabova, Olga; Makarov, Vadim; Cole, Stewart T

Piton, Jérémie; Vocat, Anthony; Lupien, Andréanne; Foo, Caroline S; Riabova, Olga; Makarov, Vadim; Cole, Stewart T.

Afiliação

Piton J; Global Health Institute, Ecole Polytechnique Fédérale de Lausanne, Lausanne, Switzerland.
Vocat A; Global Health Institute, Ecole Polytechnique Fédérale de Lausanne, Lausanne, Switzerland.
Lupien A; Global Health Institute, Ecole Polytechnique Fédérale de Lausanne, Lausanne, Switzerland.
Foo CS; Global Health Institute, Ecole Polytechnique Fédérale de Lausanne, Lausanne, Switzerland.
Riabova O; FRC Fundamentals of Biotechnology RAS, Moscow, Russian Federation.
Makarov V; FRC Fundamentals of Biotechnology RAS, Moscow, Russian Federation.
Cole ST; Global Health Institute, Ecole Polytechnique Fédérale de Lausanne, Lausanne, Switzerland stewart.cole@epfl.ch.

Antimicrob Agents Chemother ; 62(10)2018 10.

Article em En | MEDLINE | ID: mdl-30012754

Assuntos

Antituberculosos/farmacologia; Mycobacterium tuberculosis/efeitos dos fármacos; Piridazinas/farmacologia; Sulfonas/farmacologia; Proteínas de Bactérias; Desenho de Fármacos; Testes de Sensibilidade Microbiana; Relação Estrutura-Atividade; Tuberculose/microbiologia

Palavras-chave

DprE1 inhibitor; Mycobacterium tuberculosis; benzothiazinone

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Piridazinas / Sulfonas / Mycobacterium tuberculosis / Antituberculosos Idioma: En Revista: Antimicrob Agents Chemother Ano de publicação: 2018 Tipo de documento: Article País de afiliação: Suíça

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google